Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Published Online: 2011-05-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Anna Shubina•Bertrand Arnulf•Dixie-Lee Esseltine•Grigoriy Rekhtman•Halyna Pylypenko•Helgi van de Velde•Huaibao Feng•Ievgenii Karamanesht•James Cavet•Jean-Luc Harousseau•Maria Grishunina•Martin Kropff•Philippe Moreau•Sebastian Grosicki•Suzette Girgis•Tadeusz Robak•William Deraedt•Xavier Leleu•Zvenyslava Masliak
